You have made very cogent statements my friend, backed by your experience. As a physician I helped small pharma shepherd drugs through approval and devices as well. The trial design CC's calls were key. I was on the other side of the table as we developed marketing plans, speaker bureaus, etc. I would think BP will develop interest in an acquisition when the the sp is below $1.00, there is no rush at this point for them. Perhaps a merger with small to medium cash rich pharma? I have been told there is only one university immunologist that has an interest in this molecule. It is primitive compared to research efforts in immuno-oncology.

Abbvie bought Progenix and will get royalties off the gross, that may be enough for them whomever owns the company and they have a CCR5 antagonist in the pipeline. BMS already has a pipeline product as well, maraviroc goes generic this year.

Sales abroad at this time... Those countries are single payer government insurance and they have a buyers market due to the CYDY financial situation. Subtract the royalties from the gross from at least 3 entities does not leave much left.

I agree it is the only viable option.